Myelodysplastic/myeloproliferative neoplasms, unclassifiable (MDS/MPN, U): natural history and clinical outcome by treatment strategy

Leukemia. 2014 Apr;28(4):958-61. doi: 10.1038/leu.2014.8. Epub 2014 Jan 10.

Authors

C D DiNardo¹, N Daver¹, N Jain¹, N Pemmaraju¹, C Bueso-Ramos², C C Yin², S Pierce¹, E Jabbour¹, J E Cortes¹, H M Kantarjian¹, G Garcia-Manero¹, S Verstovsek¹

Affiliations

¹ Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
² Department of Hematopathology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.

No abstract available

Publication types

Letter

MeSH terms

Aged
Female
Humans
Janus Kinase 2 / antagonists & inhibitors
Male
Middle Aged
Myelodysplastic-Myeloproliferative Diseases / drug therapy
Myelodysplastic-Myeloproliferative Diseases / genetics*
Myelodysplastic-Myeloproliferative Diseases / mortality
Myelodysplastic-Myeloproliferative Diseases / pathology
Prognosis

Substances

Janus Kinase 2

Grants and funding

P30 CA016672/CA/NCI NIH HHS/United States